National Cancer Institute; Notice of Meeting, 19210-19211 [2016-07484]
Download as PDF
19210
Federal Register / Vol. 81, No. 64 / Monday, April 4, 2016 / Notices
Place: National Institutes of Health, Room
NIAID, 3C100 Resource Library, 5601 Fishers
Lane, Rockville, MD 20892 (Telephone
Conference Call).
Contact Person: Amir E. Zeituni, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
NIAID/NIH/DHHS, 5601 Fishers Lane, MSC–
9834, Rockville, MD 20852, 301–496–2550,
amir.zeituni@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS).
Dated: March 28, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–07499 Filed 4–1–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Eye Institute; Notice of Closed
Meeting
mstockstill on DSK4VPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Eye Institute
Special Emphasis Panel; NEI Secondary Data
Analysis and Conference Grant Applications.
Date: April 19–20, 2016.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Health, 5635
Fishers Lane, Rockville, MD 20814 (Virtual
Meeting).
Contact Person: Anna E. Mazzucco, Ph.D.,
Scientific Review Officer, National Eye
Institute, National Institutes of Health,
Division of Extramural Research, 5635
Fishers Lane, Suite 1300, Bethesda, MD
20852, 301–594–6074, anna.mazzucco@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.867, Vision Research,
National Institutes of Health, HHS)
VerDate Sep<11>2014
19:03 Apr 01, 2016
Jkt 238001
Dated: March 29, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–07501 Filed 4–1–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Human Genome Research
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Inherited
Disease Research Access Committee.
Date: April 29, 2016.
Time: 11:30 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5635
Fishers Lane, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Barbara J. Thomas, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, National Human Genome Research
Institute, National Institutes of Health, 5635
Fishers Lane, Ste. 4076, MSC 9306, Bethesda,
MD 20892–9306, 301–402–0838,
barbara.thomas@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.172, Human Genome
Research, National Institutes of Health, HHS)
Dated: March 29, 2016.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–07503 Filed 4–1–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
PO 00000
Frm 00099
Fmt 4703
Sfmt 4703
hereby given of a meeting of the
Frederick National Laboratory Advisory
Committee to the National Cancer
Institute.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting. The meeting
will also be videocast and can be
accessed from the NIH Videocasting and
Podcasting Web site (https://
videocast.nih.gov/).
Name of Committee: Frederick National
Laboratory Advisory Committee to the
National Cancer Institute.
Date: May 11, 2016.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: Ongoing and new activities at the
Frederick National Laboratory for Cancer
Research.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive,
Conference Room TE406, Rockville, MD
20850.
Contact Person: Peter L. Wirth, Ph.D.
Executive Secretary, National Cancer
Institute, National Institutes of Health, 9609
Medical Center Drive, Room 7W–514,
Bethesda, MD 20892, 240–276–6434, wirthp@
mail.nih.gov.
Any interested person may file
written comments with the committee
by forwarding the statement to the
Contact Person listed on this notice. The
statement should include the name,
address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NCI Shady
Grove has instituted stringent
procedures for entrance into the NCI
Shady Grove building. Visitors will be
asked to show one form of identification
(for example, a government-issued
photo ID, driver’s license, or passport)
and to state the purpose of their visit.
Information is also available on the
Institute’s/Center’s home page: https://
deainfo.nci.nih.gov/advisory/fac/
fac.htm, where an agenda and any
additional information for the meeting
will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
E:\FR\FM\04APN1.SGM
04APN1
Federal Register / Vol. 81, No. 64 / Monday, April 4, 2016 / Notices
Dated: March 29, 2016.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–07484 Filed 4–1–16; 8:45 am]
BILLING CODE 4140–01–P
Rose Freel, Ph.D., Licensing and
Patenting Manager, Technology Transfer
Center, National Cancer Institute, 8490
Progress Drive, Riverside 5, Suite 400,
Frederick, MD 21702; Telephone: (301)
624–1257; Email: rose.freel@nih.gov.
5T4 is an
antigen expressed on many different
types of cancers, especially solid
tumors. Its expression is limited in
normal tissue, but is prevalent in
malignant tumors throughout their
development making it an attractive
target for cancer immunotherapy. 5T4 is
often found in colorectal, ovarian, and
gastric tumors and as a result, has been
used as a prognostic aid for these
cancers. The role of 5T4 in antibodydirected immunotherapy has been
studied using murine monoclonal
antibodies (mAbs). In addition, the
cancer vaccine TroVax (currently in
clinical trials for multiple solid tumors)
targets 5T4. The present invention
describes the identification and
characterization of two fully human
mAbs (m1001 and m1002) that bind to
5T4. Since the mAbs are fully human,
they could have less immunogenicity
and better safety profiles than the
existing mouse and humanized
antibodies. These mAbs have the
potential to be cancer therapeutics as
naked mAbs, chimeric antigen receptors
(CARs) or antibody-drug conjugates
(ADCs).
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR part 404.7. The
prospective exclusive license may be
granted unless within fifteen (15) days
from the date of this published notice,
the National Cancer Institute receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR part 404.7.
Applications for a license in the field
of use filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive license.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
19211
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
SUPPLEMENTARY INFORMATION:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Development of 5T4
Antibodies in Human Cancer
Therapeutics and Diagnostics
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
This notice, in accordance
with 35 U.S.C. 209 and 37 CFR part 404,
that the National Cancer Institute,
National Institutes of Health,
Department of Health and Human
Services, is contemplating the grant of
an exclusive patent license to practice
the inventions embodied in the
following U.S. Patents and Patent
Applications to Ovensa, Inc. (‘‘Ovensa’’)
located in Ontario, Canada.
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
Intellectual Property
U.S. Provisional Patent Application
No. 62/034,995 filed August 8, 2014
entitled ‘‘Human Monoclonal
Antibodies Specific for 5T4 and
Methods of Their Use’’ [HHS Ref. No. E–
158–2014/0–US–01];
PCT Application No. PCT/US2015/
044253 filed August 8, 2015 entitled
‘‘Human Monoclonal Antibodies
Specific for 5T4 and Methods of Their
Use’’ [HHS Ref. No. E–158–2014/0–
PCT–02].
The patent rights in these inventions
have been assigned to the government of
the United States of America.
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to ‘‘the use
of the Licensed Patent Rights in
combination with the Licensee’s
proprietary or exclusively in-licensed
platforms and technologies for the
treatment, prevention or diagnosis of
cancer.’’
DATES: Only written comments and/or
applications for a license which are
received by the Technology Transfer
Center at the National Cancer Institute
on or before April 19, 2016 will be
considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
exclusive license should be directed to:
VerDate Sep<11>2014
19:03 Apr 01, 2016
Jkt 238001
Dated: March 29, 2016.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2016–07556 Filed 4–1–16; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00100
Fmt 4703
Sfmt 4703
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; AIDS and
Related Research NAED Conflicts.
Date: April 5, 2016.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Robert Freund, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5216,
MSC 7852, Bethesda, MD 20892, 301–435–
1050, freundr@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR16–028:
HIV/AIDS Vaccine Scholars Program.
Date: April 7, 2016.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Barna Dey, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3184,
Bethesda, MD 20892, 301–451–2796, bdey@
mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR Panel:
Multidisciplinary Studies on HIV and Aging.
Date: April 8, 2016.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\04APN1.SGM
04APN1
Agencies
[Federal Register Volume 81, Number 64 (Monday, April 4, 2016)]
[Notices]
[Pages 19210-19211]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-07484]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Meeting
Pursuant to section 10(a) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of a meeting of the
Frederick National Laboratory Advisory Committee to the National Cancer
Institute.
The meeting will be open to the public, with attendance limited to
space available. Individuals who plan to attend and need special
assistance, such as sign language interpretation or other reasonable
accommodations, should notify the Contact Person listed below in
advance of the meeting. The meeting will also be videocast and can be
accessed from the NIH Videocasting and Podcasting Web site (https://videocast.nih.gov/).
Name of Committee: Frederick National Laboratory Advisory
Committee to the National Cancer Institute.
Date: May 11, 2016.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: Ongoing and new activities at the Frederick National
Laboratory for Cancer Research.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Conference Room TE406, Rockville, MD 20850.
Contact Person: Peter L. Wirth, Ph.D. Executive Secretary,
National Cancer Institute, National Institutes of Health, 9609
Medical Center Drive, Room 7W-514, Bethesda, MD 20892, 240-276-6434,
wirthp@mail.nih.gov.
Any interested person may file written comments with the committee
by forwarding the statement to the Contact Person listed on this
notice. The statement should include the name, address, telephone
number and when applicable, the business or professional affiliation of
the interested person.
In the interest of security, NCI Shady Grove has instituted
stringent procedures for entrance into the NCI Shady Grove building.
Visitors will be asked to show one form of identification (for example,
a government-issued photo ID, driver's license, or passport) and to
state the purpose of their visit.
Information is also available on the Institute's/Center's home
page: https://deainfo.nci.nih.gov/advisory/fac/fac.htm, where an agenda
and any additional information for the meeting will be posted when
available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
[[Page 19211]]
Dated: March 29, 2016.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-07484 Filed 4-1-16; 8:45 am]
BILLING CODE 4140-01-P